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Aim: To investigate the possible association between survivin c.-31G>C (rs9904341) gene polymorphism
and urinary system cancers by ameta-analysis approach.Methods: Standard electronic literature databases
were searched to find eligible studies. The odds ratios (ORs) with 95% CIs were estimated to find the as-
sociations possibility. Results: Overall meta-analysis revealed significant associations between c.-31G>C
transversion and risk of urinary tract cancers in dominant (OR: 1.34; 95% CI: 1.02–1.75; p = 0.035), re-
cessive (OR: 1.52; 95% CI: 1.33–1.74; p < 0.001) and homozygote codominant (OR: 1.90; 95% Cl: 1.37–
2.62; p < 0.001) genetic models. Conclusion: The c.-31G>C transversion might be a risk factor for urinary
system cancers. However, more articles with different ethnicities will help to obtain a more accurate con-
clusion.
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Urinary system cancers such as prostate, kidney and bladder cancers are common forms of malignancies around
the world. The incidence of these cancers is growing due to some endogenous and exogenous factors including
smoking, obesity, alcohol use and infectious agents [1]. According to the Globocan 2012 statistics released by the
International Agency for Research on Cancer, prostate cancer is the second most frequent malignancy in the world
after lung cancer. In International Agency for Research on Cancer member countries, WHO European Region,
USA and EU prostate cancer is recognized as the first ranked most frequent cancer. Indeed, bladder cancer was
among the five types of cancer in the above-mentioned groups. Remarkably, kidney cancer is recorded among the
five most frequent cancers in the WHO European Region [2]. Since prevention is still the best way to deal with
the above-mentioned cancers, recognition of their risk factors is of great importance. There are many predisposing
genetic factors which increase the risk of urinary tract cancers [3]. Polymorphisms in the genes controlling key
cellular pathways are involved in the development of these cancers and are able to alter the risk of urinary tract
cancers. It should be noted that programmed cell death (apoptosis) is one of the most important cellular pathways
involved in cancer development and progression. Survivin protein is a key regulatory molecule in this pathway [4].
Survivin, also called BIRC5, is one member of the inhibitor of apoptosis proteins family. Survivin expression
is commonly upregulated in several cancers [5]. The role of survivin in tumorigenesis is largely dependent on its
function in apoptosis inhibition and in mitosis as a key regulator factor [6]. In typical normal cells, expression of
survivin occurs throughout embryonic and fetal developmental periods. Survivin level is practically invisible in
differentiated adult cells [5]. So, upregulation of this gene in most tumor cells makes it a valuable biomarker for
diagnosis and treatment of cancer [7].
The survivin gene, located at 17q25.3, encodes a proteinwhich contains a BIR (baculoviral IAP repeat) domain [8].
There are numerous variations in this gene and the c.-31G>C (rs9904341) is a well-known single nucleotide
polymorphism (SNP) in the upstream of this gene. This SNP is positioned in the CDE/CHR repressor region of
survivin and it might lead to overexpression of the gene [5]. Our literature review showed that this polymorphism is
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associated with urinary system cancers, but the results of studies are inconclusive. Therefore, we aimed to evaluate
the association between c.-31G>C polymorphism and urinary system cancers through a meta-analysis.
Methods
Search strategy
The current meta-analysis is in accordance with the PRISMA checklist (Supplementary Table 1) and included a
relevant paper studying the association between rs9904341 gene transversion and urinary system cancers. To find
all aforementioned papers, two authors (A Karimian and M Karimian) independently performed a comprehensive
literature search in PubMed, ISI Web of Science, ScienceDirect and Google Scholar databases up to June 2018
by using the following keywords: ‘survivin or BIRC5’ and ’c.-31G>C or rs9904341’, and ‘polymorphism or SNP
or variant or variation’ and ‘prostate or bladder or renal cell carcinoma or urinary tract cancer’. Moreover, the
references of retrieved papers were assessed to recognize other qualified articles that were missing out on the chief
search.
Inclusion & exclusion criteria
The case reports, review articles and editorials were excluded from the meta-analysis. Studies with the following
criteria were considered eligible for inclusion to the meta-analysis: studies investigating the association of survivin
c.-31G>C polymorphism with urinary system cancers such as prostate, bladder and renal cell carcinoma; studies
with case-control design; and studies with sufficient data to calculate odds ratio (OR) and 95% CI.
Data extraction strategy
Two abovementioned authors carefully extracted the following information from all eligible studies: name of first
author, publication year, the country (ethnicity), source of controls, type of cancer, genotyping methods, and allele
and genotype frequencies of cases and controls. Disagreements about extracted data were solved by consensus and
argument.
Statistical analysis
The Hardy–Weinberg equilibrium (HWE), base on genotype frequencies in control groups of each studies, was
calculated by a Chi-squared test. The ORs with a 95%CI were estimated using random-effect or fixed-effect models
based on the heterogeneity results. Random-effects model was selected if the p-value of the heterogeneity test was less
than 0.1 otherwise the fixed-effects model was chosen. Cochran’s Q test with inconsistency index (I 2) was applied
for the calculation of heterogeneity across studies [9,10]. Meta-analysis was performed for the five following genetic
models: C versus G (allelic), CC versus GG (homozygote codominant), GC versus GG (heterozygote codominant),
GC +CC versus GG (dominant) and CC versus GG +GC (recessive). Also, meta-analysis was stratified for cancer
type, source of controls, HWE status of control groups, sample size and ethnicity subgroups. Publication bias was
evaluated by Begg’s funnel plots and the Egger’s test [11,12]. Finally, the sensitivity analysis was performed using
removing one study at a time to determine themagnitude of the effect on the total assessment. All of these calculations
were performed by the Open meta analyst (Tufts University, MA, USA; www.cebm.brown.edu/openmeta/) and
Comprehensive meta analysis (Biostat, Inc., NJ, USA; www.meta-analysis.com/) software.
Results
Study characteristics
The flowchart of searching and screening procedure is displayed in Figure 1. At first, a total of 79 papers were
recognized by systematic search in electronic databases. After employing selection criteria, seven eligible articles
reporting the association of the c.-31G>C polymorphism with urinary system cancers risk were included into
the meta-analysis [13–19]. Some information of these studies such as cancer type, source of control, ethnicity and
sample size were extracted and listed in Table 1. Of these seven studies, five studies were conducted in Asian and
two studies were belonged to Caucasian populations. Moreover, two studies focused on renal cell carcinoma, two
on bladder cancer, two on prostate cancer and one on urothelial cancer. The genotype frequencies in the control
groups of two studies were deviated from HWE. The control groups of six studies were hospital based and one
remaining was population based (Table 1).
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Overall studies recognized from electronic
databases (n = 79)
Irrelevant studies (n = 34)
Additional papers
recognized from citations
of main search (n = 4)
Overall papers collected from electronic
databases and citations (n = 49)
Studied other cancers
except urinary tract (n = 21)
Review articles (n = 3)
Eligible studies included in
the mata-analysis (n = 7)
Studied other SNPs except
c.-31G > C (n = 18)
Figure 1. Results of the search strategy and the reasons for exclusion.
SNPs: Single-nucleotide polymorphisms.
Association of c.-31G>C with urinary cancers risk
The chief results of themeta-analysis are detailed in Table 2. Overall, we observed significant associations between c.-
31G>C transversion and risk of urinary tract cancer in homozygote codominant (Figure 2A), dominant (Figure 2B)
and recessive (Figure 2C) genetic models. When the analysis was stratified by cancer type, we observed an increased
risk for bladder cancer, renal cell carcinoma and prostate cancer. Also, significant associations were observed for
hospital based studies. Stratified analysis by HWE status of control groups showed that there were significant
associations for studies with P HWE> 0.05 and P HWE< 0.05. After analysis of ethnicity subgroups, we observed
that there were significant associations for Caucasians and Asians. Moreover, after stratified analysis by sample sizes
of studies, we observed significant associations for studies with less than 1000 and more than 1000 participants
(Table 2).
Heterogeneity, publication bias & sensitivity analysis
Significant heterogeneities were found in overall analysis (C vs G: P heterogeneity< 0.001, I 2 = 96%; CC vs GG: P
heterogeneity = 0.002; I 2 = 71%; GC vs GG: P heterogeneity< 0.001, I 2 = 75%; GC + CC vs GG: P heterogeneity< 0.001,
I 2 = 76%). Therefore, we applied a random-effects model with wider CIs to estimate the association results. Our
data revealed that true heterogeneities remain after stratified analyses by source of control, HWE status, ethnicity
and sample size. However, when the stratification was done based on the cancer type, heterogeneities significantly
disappeared (Table 3). Both Begg’s funnel plot and Egger’s test were used to assess the publication bias. The results
of Egger’s tests are summarized in Table 3. In overall meta-analysis, there is only a significant publication bias
in the genetic model (p = 0.014). Also, qualitative results of publication bias showed a symmetrical distribution
for the mentioned analysis in allelic (Figure 3A), homozygote codominant (Figure 3B), heterozygote codominant
(Figure 3C) and dominant (Figure 3D) genetic models. Also, publication biases were observed for receive model
after stratification by the source of control (p = 0.027), HWE status of the control group (p = 0.006), and ethnicity
(p = 0.010). To detect the impact of the single dataset on the pooled ORs, we excluded an individual study from
10.2217/pme-2018-0053 Per. Med. (Epub ahead of print) future science group
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Wang et al., 2009
Kawata et al., 2011
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Jaiswal et al., 2012
Chen et al., 2013
Marques et al., 2013
Karimian et al., 2018
Overall (I2 = 23%, p = 0.255)
Studies
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Odds ratio (log scale)
Wang et al., 2009
Kawata et al., 2011
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Jaiswal et al., 2012
Chen et al., 2013
Marques et al., 2013
Karimian et al., 2018
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Wang et al., 2009
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Figure 2. Forest plot for the association of c.-31G>C polymorphism of survivin gene with urinary system cancers in
overall analysis. Significant association was observed in homozygote codominant (A), dominant (B) and recessive (C)
genetic models.
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Figure 3. Funnel plot for association of c.-31G>C polymorphism of survivin gene with urinary system cancers in
overall analysis. An symmetrical distribution was found in allelic (A), homozygote codominant (B), heterozygote
codominant (C) and dominant (D) genetic models.
the meta-analysis each time and then recalculated ORs. Our results showed that the respective pooled ORs was not
substantially chanced (data not shown), suggesting that the meta-analysis were statistically robust.
Discussion
Some epidemiological studies have investigated the association of survivin c.-31G>C polymorphism with the
urinary tract cancers risk, but the results of these studies are inconclusive and sometimes they might be inconsistent.
This may arise from the limitations of single studies. Meta-analysis has been widely used in epidemiological
studies; mostly for the evaluation of gene polymorphisms for cancer susceptibility. It could make better statistical
potency, subsequently obtaining a more accurate conclusion [20]. Therefore, we used a meta-analysis to find out
the association of c.-31G>C transversion with the urinary cancers risk. The data from our meta-analysis showed
that there is a significant association between c.-31G>C polymorphism and risk of urinary cancers in several
genetic models with a true heterogeneity. Also, stratified meta-analysis showed that significant associations remain
significant. Of course, the significant heterogeneities disappear after stratifying by cancer type; therefore, it may
be source of heterogeneities. In the meta-analysis, we did not observe main publication biases and also sensitivity
analysis showed our meta-analysis is reliable and robust.
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Figure 3. Funnel plot for association of c.-31G>C polymorphism of survivin gene with urinary system cancers in
overall analysis (cont.). An symmetrical distribution was found in allelic (A), homozygote codominant (B),
heterozygote codominant (C) and dominant (D) genetic models.
Our study showing the association of c.-31G>C polymorphism with risk of urinary system cancers is biolog-
ically reasonable. It is largely approved that changes in the expression profile of antiapoptotic and proapoptotic
proteins [21,22] could result in cancer’s resistance to apoptosis. Survivin, an antiapoptotic molecule, has a main
role in the pathway of apoptosis and also in cell proliferation. Evidence is expanding that survivin was strikingly
upregulated in several human cancers cells, consisting with the deregulated apoptosis in tumor cells [17,23]. Genetic
variations including SNPs could alter the mRNA structure, gene expression pattern and protein function [24–26].
The exact mechanism explaining the association of rs9904341 with risk of urinary system cancers is still unclear.
Some reports proposed that key genetic variations could change the expression of survivin gene. Upregulation of
survivin made by mentioned key SNPs may reduce apoptotic capacity and increase tumor development [27]. The
c.-31G>C SNP can interrupt the CDE/CHR repressor element and then increase the survivin overexpression. In
vitro examination also showed that c.-31G allele is less active transcriptionally rather than c.-31C allele so, c.-31CC
genotype will have overexpression of survivin gene [28]. Nikiteas et al. discovered that survivin mRNA expression
of -31CC homozygous phenotype were around 1.6-times greater than GG and GC phenotypes [29]. Xu et al. also
established that the incidence of variation including rs9904341 SNP was associated with up-regulation of survivin
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in some cell lines [30]. Regarding these explanations, we expected that surviving possibility contributed to increasing
the urinary system cancers risk, and our study established this suggestion.
Some latest papers displayed that using in silico tools could be a beneficial attitude to comprehend and deduce
the polymorphism influences more precisely [31,32]. In our previous study, we employed in silico software to predict
the impacts of c.-31G>C polymorphism in function of survivin gene [19]. We found that the mentioned SNP
cause to change in regulation of survivin transcription. We reported that it may change interactions of transcription
factors with the promoter region and it may influence survivin gene expression. Also, we found that, c.-31G>C
polymorphism happens in a CpG island and any change in this region may influence methylation profile of the
promoter [19]. CpG Islands methylation has been broadly defined as a mechanism related with regulation of gene
expression [33] particularly in prostate malignancy [34].
There are some limitations in this study which should be considered. We did not access to original data such
as age, BMI, Gleason score, etc. to adjust the results in the meta-analysis. Also, there were no paper investigating
the association of c.-31G>C polymorphism with urinary system cancers in African and Latino population.
Furthermore, we did not include the non-English articles that it may result in language bias.
Conclusion & future perspective
The survivin c.-31G>C mutation could increase the risk of urinary system cancer. However, a meta-analysis with
more articles and different ethnicities will help to obtain a more accurate conclusion. Regard to the rate and
increase of urinary system cancers worldwide, prevention of these cancers could be the best way to deal with them.
Therefore, recognizing the risk factors of urinary system cancers has a high value. Many risk factors for the diseases
have been identified that the role of genetic factors is noteworthy. In the meantime, c.-31G>C polymorphism as
a genetic risk factor could be a helpful molecular biomarker for screening of susceptible individuals to mentioned
cancers.
Executive summary
• Polymorphisms in survivin may alter the risk of cancer susceptibility.
• Association of survivin c.-31G>C gene polymorphism with urinary system cancers was investigated by a
meta-analysis.
• Significant associations between c.-31G>C polymorphism and risk of urinary tract cancers were found in overall
and stratified meta-analysis.
• The survivin c.-31G>C polymorphism may be a genetic risk factor for urinary system cancer.
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